Prolonged n‐3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non‐alcoholic fatty liver disease: a pilot study

Capanni, M.; Calella, Francesca; Biagini, Maria Rosa; Genise, S.; Raimondi, Laura; Bedogni, Giorgio; Svegliati‐Baroni, Gianluca; Sofi, Francesco; Milani, Stefano; Abbate, Rosanna; Surrenti, C.; Casini, Alessandro

doi:10.1111/j.1365-2036.2006.02885.x

Cited by 377 publications

(291 citation statements)

References 43 publications

Supporting

Mentioning

258

Contrasting

Unclassified

Order By: Relevance

“…139 Omega-3 fatty acids, currently approved in the United States to treat hypertriglyceridemia, have been investigated to treat NAFLD both in animal models and in humans. 141 A recent review by Masterton et al, 142 of published literature related to omega-3 fatty acids in NAFLD, found experimental evidence to support their use but the interpretation of human studies was limited by small sample size and methodological flaws. A large multicenter study of one omega-3 fatty acid (eicosapentanoic acid) to treat NASH is ongoing in the United States.. More than a dozen other miscellaneous agents have been investigated in small, proof-of-concept studies and their detailed evaluation is beyond the scope of this guideline.…”

Section: Vitamin Ementioning

confidence: 99%

The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

et al. 2012

View full text Add to dashboard Cite

Section: Vitamin Ementioning

confidence: 99%

The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

et al. 2012

View full text Add to dashboard Cite

“…4 This effect is attributable mainly to the combined effects of inhibition of lipogenesis and stimulation of fatty acid oxidation in the liver. 5,6 Fish oil supplementation may be effective in the prevention of NAFLD; however, it is not clear whether fish oil is effective against all types of fatty liver.…”

mentioning

confidence: 99%

Fish oil prevents sucrose-induced fatty liver but exacerbates high-safflower oil-induced fatty liver in ddy mice

Yamazaki

Nakamori²,

Sasaki³

et al. 2007

Hepatology

View full text Add to dashboard Cite

Diets high in sucrose/fructose or fat can result in hepatic steatosis (fatty liver). We analyzed the effects of dietary fish oil on fatty liver induced by sucrose, safflower oil, and butter in ddY mice. In experiment I, mice were fed a high-starch diet [70 energy% (en%) starch] plus 20% (wt/wt) sucrose in the drinking water or fed a high-safflower oil diet (60 en%) for 11 weeks. As a control, mice were fed a high-starch diet with drinking water. Fish oil (10 en%) was either supplemented or not. Mice supplemented with sucrose or fed safflower oil showed a 1.7-fold or 2.2-fold increased liver triglyceride content, respectively, compared with that of control mice. Fish oil completely prevented sucrose-induced fatty liver, whereas it exacerbated safflower oil-induced fatty liver. Sucrose increased SREBP-1c and target gene messenger RNAs (mRNAs), and fish oil completely inhibited these increases. In experiment II, mice were fed a high-safflower oil or a high-butter diet, with or without fish oil supplementation. Fish oil exacerbated safflower oilinduced fatty liver but did not affect butter-induced fatty liver. Fish oil increased expression of peroxisome proliferator-activated receptor gamma (PPAR␥) and target CD36 mRNA in safflower oil-fed mice. These increases were not observed in sucrose-supplemented or butter-fed mice. Conclusion: The effects of dietary fish oil on fatty liver differ according to the cause of fatty liver; fish oil prevents sucrose-induced fatty liver but exacerbates safflower oil-induced fatty liver. The exacerbation of fatty liver may be due, at least in part, to increased expression of liver PPAR␥.

show abstract

“…More importantly, most of the studies did not evaluate histological endpoints of treatment. Among the first trials, Capanni et al found that PUFA improved liver aminotransaminases, metabolic profiles and hepatic steatosis on imaging [54]. Other studies have provided collaborative observations [53].…”

Section: Thiazolidinedionesmentioning

confidence: 98%

Pharmacologic Management of Non-Alcoholic Fatty Liver Disease

Goh¹,

Dasarathy²,

McCullough³

2014

Adv Pharmacoepidemiol Drug Saf

View full text Add to dashboard Cite

Background: Non-alcoholic fatty liver disease (NAFLD) is a common complex chronic liver disease that encompasses a spectrum of disease from simple steatosis to non-alcoholic steatohepatitis (NASH). NASH has the potential to progress to advanced fibrosis and cirrhosis and is associated with increased morbidity and mortality. Currently, there are no definitive universally accepted treatment options available for NASH. Most pharmacological agents that have been investigated are limited by inconsistent efficacy or side effects. We reviewed the current literature on the principle drugs that have been tested for NAFLD in the adult population, with special emphasis on clinical data and safety profiles. Methods:A comprehensive PUBMED/MEDLINE search was conducted to identify principal therapeutic intervention studies for NAFLD, from which a summary of the studies were formulated in this review. Results:A variety of studies, including retrospective, open-label and randomised controlled trials were reviewed in terms of clinical efficacy and side effect profiles. In addition to the most commonly studied therapeutic agents (insulin sensitizers, vitamin E, pentoxifylline, UDCA, PUFA, statins and ezetimibe), emerging pharmacologic agents showing potential efficacy in NAFLD were also explored. Conclusion:Based on risk-benefit profiles, pentoxifylline seems to have the best treatment outcomes currently, with significant improvement in histology while having minimal tolerable side effects. Further clinical research is warranted to understand and improve our repertoire of treatment options, including potential combination therapy, towards this complex disease.

show abstract

Prolonged n‐3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non‐alcoholic fatty liver disease: a pilot study

Abstract: SUMMARY BackgroundRecent studies suggest a role of n-3 long-chain polyunsaturated fatty acids (n-3 PUFA) as peroxisome proliferator-activated receptor-a ligands in improving non-alcoholic fatty liver disease (NAFLD) in rodents. However, data in humans are still lacking.

Cited by 377 publications

References 43 publications

The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

Fish oil prevents sucrose-induced fatty liver but exacerbates high-safflower oil-induced fatty liver in ddy mice

Pharmacologic Management of Non-Alcoholic Fatty Liver Disease

Contact Info

Product

Resources

About